Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Lancet Oncol. 2022 Jun;23(6):818-828. doi: 10.1016/S1470-2045(22)00220-0.
Lancet Oncol. 2022.
PMID: 35654052
Clinical Trial.
IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study.
Rotbain EC, Frederiksen H, Hjalgrim H, Rostgaard K, Egholm GJ, Zahedi B, Poulsen CB, Enggard L, da Cunha-Bang C, Niemann CU.
Rotbain EC, et al.
Haematologica. 2020 Jun;105(6):1621-1629. doi: 10.3324/haematol.2019.220194. Epub 2019 Oct 3.
Haematologica. 2020.
PMID: 31582540
Free PMC article.
Item in Clipboard
Cite
Cite